Australia's LT Pharma gains after nod to test nasal spray

Ltr Pharma

24/06/2026 06:08

** LT Pharma shares LTP.AX rise as much as 14.2% to A$0.645, their highest level since January 9
** *Biopharmaceutical co says its novel nasal spray receives ethics approval to conduct study evaluating its effects in patients with Oesophageal Motility Disorders (OMD)
** Marks co's entry into the gastrointestinal diseases market, where OMD treatments alone are expected to reach $8.1 billion by 2034
** 1.3 million shares traded so far vs 30-day average of 532,000
** Stock down over 11% YTD

(Reporting by Shravya Marakini in Bengaluru)
((shravya.marakini@thomsonreuters.com))